BSW Wealth Partners Purchases 5,000 Shares of ChromaDex Co. (NASDAQ:CDXC)

BSW Wealth Partners increased its holdings in ChromaDex Co. (NASDAQ:CDXC) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,847 shares of the company’s stock after buying an additional 5,000 shares during the quarter. BSW Wealth Partners’ holdings in ChromaDex were worth $498,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CDXC. Geode Capital Management LLC raised its stake in ChromaDex by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after acquiring an additional 17,963 shares during the period. State Street Corp raised its position in shares of ChromaDex by 11.3% during the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the period. Renaissance Technologies LLC lifted its stake in shares of ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after buying an additional 32,400 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in ChromaDex by 11.1% during the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock valued at $1,211,000 after acquiring an additional 33,150 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of ChromaDex by 10.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company’s stock valued at $639,000 after acquiring an additional 17,115 shares in the last quarter. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Price Performance

NASDAQ:CDXC opened at $5.90 on Thursday. The company has a market cap of $450.64 million, a price-to-earnings ratio of 590.59 and a beta of 2.21. ChromaDex Co. has a 1 year low of $1.46 and a 1 year high of $7.97. The stock’s 50 day simple moving average is $6.14 and its two-hundred day simple moving average is $4.64.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. As a group, analysts anticipate that ChromaDex Co. will post 0.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CDXC shares. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 15th. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Roth Mkm lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.